Table 4. Change in Harrell’s C-statistic for prediction of all-cause mortality, composite and fatal CVD outcomes and end-stage kidney disease in those with ≥ 20% absolute discordance between eGFRcr and eGFRcys.
| N cases | C-statistic | Change in C-statistic | P value | |
|---|---|---|---|---|
| All-cause mortality | 6557/183867 | 0.7207 (0.7140-0.7275) | na | |
| + eGFRcr | 0.7270 (0.7203-0.7337) | 0.0063 (0.0042-0.0084) | <0.001 | |
| + eGFRcys | 0.7343 (0.7277-0.7410) | 0.0136 (0.0108-0.0165) | <0.001 | |
| + eGFRcr-cys | 0.7246 (0.7178-0.7312) | 0.0038 (0.0023-0.0054) | <0.001 | |
| Composite CVD | 3565/183867 | 0.7422 (0.7338-0.7505) | na | |
| + eGFRcr | 0.7425 (0.7341-0.7508) | 0.0003 (-0.0003-0.0009) | 0.347 | |
| + eGFRcys | 0.7469 (0.7386-0.7552) | 0.0047 (0.0027-0.0067) | <0.001 | |
| + eGFRcr-cys | 0.7448 (0.7365-0.7532) | 0.0027 (0.0012-0.0042) | <0.001 | |
| Fatal CVD | 1059/183867 | 0.7947 (0.7806-0.8088) | na | |
| + eGFRcr | 0.7965 (0.7823-0.8107) | 0.0018 (-0.0013-0.0049) | 0.264 | |
| + eGFRcys | 0.8036 (0.7897-0.8175) | 0.0089 (0.0036-0.0141) | 0.001 | |
| + eGFRcr-cys | 0.7979 (0.7839-0.8119) | 0.0032 (-0.0001-0.0065) | 0.057 | |
| ESKD | 52/183867 | 0.7200 (0.6332-0.8068) | na | |
| + eGFRcr | 0.7215 (0.6363-0.8067) | 0.0015 (-0.0027-0.0058) | 0.483 | |
| + eGFRcys | 0.7301 (0.6378-0.8223) | 0.0101 (-0.0473-0.0675) | 0.730 | |
| + eGFRcr-cys | 0.7446 (0.6649-0.8244) | 0.0246 (-0.0337-0.0830) | 0.408 |
C-statistics and change in C-statistic for Cox proportional hazard models adjusted for atherosclerotic risk factors (age, sex, ethnicity, smoking, systolic and diastolic blood pressure, antihypertensive medications, statins, total and high-density lipoprotein (HDL) cholesterol) and log urine albumin:creatinine ratio (uACR) with addition of the three estimated glomerular filtration rate (eGFR) methods: eGFR based on creatinine (eGFRcr), eGFR based on cystatin C (eGFRcys) and eGFR based on creatinine and cystatin C (eGFRcr-cys).